Public Health Emergency of International Concern (PHEIC)

Polio this week as of 25 March 2020
:: The COVID-19 emergency means that many aspects of the polio eradication programme will be affected. In light of the situation, the Polio Oversight Board (POB) has come up with a set of recommendations for polio eradicators…[See Milestones above for detail]

Summary of new viruses this week (AFP cases and ES positives):
:: Afghanistan: four WPV1 positive environmental samples
:: Pakistan: two WPV1 cases and six WPV1 positive environmental samples
:: Central African Republic: one cVDPV2 positive environmental sample
:: Angola: two cVDPV2 cases
:: Cameroon: one cVDPV2 case and three cVDPV2 positive environmental samples
:: Chad: five cVDPV2 cases and two cVDPV2 positive environmental samples
:: Côte d’Ivoire: two cVDPV2 positive environmental sample
:: Ethiopia : three cVDPV2 cases
:: Malaysia: one cVDPV1 case
:: Ghana: two cVDPV2 positive environmental samples


WHO Grade 3 Emergencies [to 28 Mar 2020]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 85: 24 March 2020
[See Ebola above for detail]

Mozambique floods
:: World Health Organization: Five cases of COVID-19 confirmed in Mozambique 26 March 2020

Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified
Syrian Arab Republic – No new digest announcements identified
Yemen – No new digest announcements identified


WHO Grade 2 Emergencies [to 28 Mar 2020]
:: Niger : Table ronde des PTF pour le financement du plan global de réponse à la pandé…
26 mars 2020

Afghanistan – No new digest announcements identified
Angola – No new digest announcements identified
Burkina Faso [in French] – No new digest announcements identified
Burundi – No new digest announcements identified
Cameroon – No new digest announcements identified
Central African Republic – No new digest announcements identified
Ethiopia – No new digest announcements identified
HIV in Pakistan – No new digest announcements identified
Iran – No new digest announcements identified
Iraq – No new digest announcements identified
Libya – No new digest announcements identified
Malawi – No new digest announcements identified
Measles in Europe – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Myanmar – No new digest announcements identified
occupied Palestinian territory – No new digest announcements identified
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified


WHO Grade 1 Emergencies [to 28 Mar 2020]

Chad – No new digest announcements identified
Djibouti – No new digest announcements identified
Kenya – No new digest announcements identified
Mali – No new digest announcements identified
Namibia – viral hepatitis – No new digest announcements identified
Tanzania – No new digest announcements identified


UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: Recent Developments in Northwest Syria – Situation Report No. 11 – As of 27 March 2020
:: Syrian Arab Republic: COVID-19 Update No. 03 – 25 March 2020

Yemen – No new digest announcements identified


UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
CYCLONE IDAI and Kenneth – No new digest announcements identified
EBOLA OUTBREAK IN THE DRC – No new digest announcements identified


WHO & Regional Offices [to 28 Mar 2020]

WHO & Regional Offices [to 28 Mar 2020]
26 March 2020 News release
WHO Director-General calls on G20 to Fight, Unite, and Ignite against COVID-19

25 March 2020 News release
How to budget for COVID-19 response?

24 March 2020 News release
New WHO recommendations to prevent tuberculosis aim to save millions of lives

23 March 2020 News release
Pass the message: Five steps to kicking out coronavirus



Preferred Product Characteristics of Monoclonal Antibodies for Passive Immunization against Respiratory Syncytial Virus (RSV)pdf, 206kb
26 March 2020
PPC: Call for comments by 10 May 2020: Draft Version 0.1 for public consultation
Comment Form – PPC RSV mAbsdocx, 14kb

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An action framework
25 March 2020
Draft technical WHO document (11 March 2010) open for public review until 30th March 2020.
Annex to Immunization Agenda 2030



Weekly Epidemiological Record, 27 March 2020, vol. 95, 13 (pp. 117–132)
:: Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness
:: Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2020



WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
No new digest content identified.

WHO Region of the Americas PAHO
:: La OMS lleva la información de la COVID-19 a millones a través de WhatsApp, ahora en español (03/27/2020)
:: Similarities and differences – COVID-19 and influenza (03/26/2020)

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: Mental health and psychological resilience during the COVID-19 pandemic 27-03-2020
:: Food and nutrition tips during self-quarantine 27-03-2020
:: Physical and mental health key to resilience during COVID-19 pandemic 26-03-2020
:: How to stay physically active during COVID-19 self-quarantine 25-03-2020
:: Reduction in tuberculosis cases but Europe on course to miss eradication target 24-03-2020

WHO Eastern Mediterranean Region EMRO
:: Statement by the Regional Director Dr Ahmed Al-Mandhari on COVID-19 in the Eastern Mediterranean Region
27 March 2020, Cairo, Egypt – 21 out of 22 countries in the Eastern Mediterranean region are now reporting cases of COVID-19, including new reports of 5 confirmed cases in Syria and one confirmed case Libya. The past weeks have seen some of the most developed health systems in the world struggle with their response to COVID-19.
:: WHO delegation concludes COVID-19 technical mission to Egypt 26 March 2020
:: WHO, Saudi Arabia join forces to fight COVID-19 nationally, regionally and globally 25 March 2020

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 28 Mar 2020]

CDC/ACIP [to 28 Mar 2020]
Latest News Releases
CDC Statement on COVID-19 Apple App
Friday, March 27, 2020
Today, Apple Inc. – in partnership with the White House Coronavirus Task Force and the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention (CDC) – released an app and website that guides Americans through a series of questions about their health and exposure to determine if they should seek care for COVID-19 symptoms.  The tool provides CDC recommendations on next steps including guidance on social distancing and self-isolating, how to closely monitor symptoms, recommendations on testing, and when to contact a medical provider.
This launch is a direct response to President Trump’s call for an all-of-America approach and will help Americans heed CDC guidelines and self-isolate to limit COVID-19 transmission.
Users can download the free app from Apple’s App Storeexternal icon or access the tool online at www.apple.com/covid19external icon.  Everyone has a role to play as we work together to stop the spread of COVID-19.  The latest recommendations can be found at www.coronavirus.govexternal icon.

CDC Statement on Self-Quarantine Guidance for Greater New York City Transportation and Delivery Workers
Thursday, March 26, 2020
When we issued the self-quarantining guidance for greater New York City residents leaving this area, it was out of an abundance of caution to help protect U.S. areas with lower levels of COVID-19 spread. In line with our recommendations for other essential critical infrastructure workers, this guidance does not apply to critical transportation and delivery workers who are desperately needed for New York residents to continue their daily lives and respond to the COVID-19 outbreak.
Truck drivers and other people driving into the city to deliver needed supplies should stay in their vehicles as much as possible as supplies are loaded and unloaded, avoid being within 6 feet of others as much as possible when they exit their vehicles, and move to electronic receipts if possible. If these drivers need to spend the night in the greater New York City area, they should stay in their hotel rooms or sleeper cab, when available, to the extent possible and continue to practice social distancing. Drivers who take these precautions should not need to self-quarantine when they leave the greater New York area, unless self-quarantine is recommended by state or local officials for all residents in the areas where they live.
Truck drivers and other workers who obtain or deliver needed supplies who live in the greater New York area may continue to work both within and outside of the greater New York area but should stay at home and practice social distancing according to instructions of state and local officials when they are not working. While they are working either within or outside of the greater New York area, they should stay in their vehicles as much as possible, avoid being within 6 feet of others as much as possible when they exit their vehicles, and move to electronic receipts if possible.
We continue to recommend that all people take precautions to stay safe and keep others safe, including washing their hands regularly, staying home when sick, covering coughs and sneezes, and maintaining distance from others.
It remains our guidance that residents who were recently in the affected areas of New York, out of an abundance of caution, should self-quarantine for 14 days.

China CDC

China CDC
No new digest content identified.


National Health Commission of the People’s Republic of China
Xi chairs politburo meeting to consolidate gains in outbreak response and economic resurgence
General Secretary Xi Jinping chaired a meeting of the Political Bureau of the Central Committee of the Communist Party of China on March 27 to assess response to the COVID-19 outbreak and state of the economy in and beyond China and to discuss further plans to both defeat the virus and ensure economic and social development.
Reviewing significant developments in outbreak control and economic performance at home and broad, the Political Bureau underscored that the accelerating spread of COVID-19 outside China has seriously impacted the global economy and trade. It is also making it harder to prevent the importation of cases and putting greater strains on economic growth and particularly the restoration of industrial chains in China…

March 28: Daily briefing on novel coronavirus cases in China
On March 27, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 54 new cases of confirmed infections (all are imported cases), 29 new cases of suspected infections, and 3 deaths (all in Hubei province). 383 patients were released from hospital after being cured. 758 people who had had close contact with infected patients were freed from medical observation. Serious cases decreased by 113.

China puts major restrictions on inbound air travel
China was compelled to temporarily suspend entry into the country of foreign passport holders with valid visas or residence permits in order to deal with the spread of COVID-19, Foreign Ministry spokesman Geng Shuang said on March 27.
“We also took into account the practices of many other countries,” Geng said at a regular news conference in Beijing.
He said China will stay in close touch with all parties and properly handle personnel exchanges with the rest of the world.
The suspension, announced on March 26, will take effect on March 28, and will also apply to the entry of foreign nationals holding Asia-Pacific Economic Cooperation business travel cards…

Wuhan risk level lowered as outbreak intercepted

Specialists from China, US share COVID-19 knowledge



Paul G. Allen Frontiers Group    [to 28 Mar 2020]
Press Release
No new digest content identified.
BMGF – Gates Foundation  [to 28 Mar 2020]
MARCH 25, 2020
Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic Alongside Bill & Melinda Gates Foundation
Collaboration to address product development and scale-up challenges posed by the current pandemic

MARCH 24, 2020
Bill & Melinda Gates Foundation Shares Details for Greater Seattle Area Coronavirus Response Grants
Grants include support for vulnerable communities and public information campaign

Bill & Melinda Gates Medical Research Institute    [to 28 Mar 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 28 Mar 2020]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
CEPI – Coalition for Epidemic Preparedness Innovations  [to 28 Mar 2020]
Latest News
UK boosts support for CEPI to spur COVID-19 vaccine development

26 Mar 2020
UK Prime Minister, Boris Johnson, announced today a £210 million (US$270 million) boost in funding for CEPI. The announcement followed a virtual conference with G20 leaders and acknowledged the coalition’s recent global call for $2 billion to progress COVID-19 vaccines through to manufacture.
Clinton Health Access Initiative, Inc. (CHAI)  [to 28 Mar 2020]
News & Press Releases
No new digest content identified.
EDCTP    [to 28 Mar 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
24 March 2020
Total EDCTP investment in TB research & development rises to € 228 million
On World TB Day 2020, the COVID-19 pandemic is a stark reminder of the global impact and burden of infectious diseases on individual and public health, society and national economies. Since 1997, the World Health Organisation (WHO) has reported on…
Emory Vaccine Center    [to 28 Mar 2020]
No new digest content identified.
European Medicines Agency  [to 28 Mar 2020]
News & Press Releases
Press release: EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic
Last updated: 27/03/2020
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020
CHMP, Last updated: 27/03/2020
Press release: Global regulators map out data requirements for phase 1 COVID-19 vaccine trials
Last updated: 24/03/2020
Press release: COVID-19: Beware of falsified medicines from unregistered websites
Last updated: 24/03/2020
European Vaccine Initiative  [to 28 Mar 2020]
Latest News
No new digest content identified.
FDA [to 28 Mar 2020]
Press Announcements
March 27, 2020 – Coronavirus (COVID-19) Update: Daily Roundup March 27, 2020
March 27, 2020 – Coronavirus (COVID-19) Update: FDA takes action to help increase U.S. supply of ventilators and respirators for protection of health care workers, patients
March 26, 2020 – Coronavirus (COVID-19) Update: Daily Roundup March 26, 2020
March 26, 2020 – FDA Continues to Support Transparency and Collaboration in Drug Approval Process as the Clinical Data Summary Pilot Concludes
March 25, 2020 – Coronavirus (COVID-19) Update: Daily Roundup, March 25, 2020
March 24, 2020 – Coronavirus (COVID-19) Update: Daily Roundup, March 24, 2020
March 24, 2020 – Coronavirus (COVID-19) Update: FDA takes action to increase U.S. supplies through instructions for PPE and device manufacturers
March 24, 2020 – Coronavirus (COVID-19) Update: FDA Helps Facilitate Veterinary Telemedicine During Pandemic
March 22, 2020 – Coronavirus (COVID-19) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency
March 22, 2020 – Coronavirus (COVID-19) Update: FDA Continues to Facilitate Access to Crucial Medical Products, Including Ventilators
Fondation Merieux  [to 28 Mar 2020]
News, Events
No new digest content identified.
Gavi [to 28 Mar 2020]
Top Stories
26 March 2020
Gavi applauds G20 Leaders’ commitment to supporting the global effort against COVID-19
26 March 2020
What is herd immunity?
26 March 2020
How do we stop the spread of a pandemic in a slum?
GHIT Fund   [to 28 Mar 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.
Global Fund  [to 28 Mar 2020]
News & Stories
Re-thinking Global Health Security
27 March 2020
Sourcing & Management of Health Products
COVID-19 Impact on Supply Chain Logistics: Assessment and Recommendations
27 March 2020

Japan Secures $476 million Contribution to the Global Fund
27 March 2020

Funding Model
First Funding Requests Submitted in the 2020-2022 Funding Cycle
26 March 2020

When Finance Fails: Why Economists Didn’t See a Coronavirus Collapse Coming
25 March 2020

Fighting Tuberculosis: Lessons for COVID-19
23 March 2020

Global Fund Supports Countries in Response to COVID-19
23 March 2020
Hilleman Laboratories   [to 28 Mar 2020]
No new digest content identified.
Human Vaccines Project   [to 28 Mar 2020]
Press Releases
No new digest content identified.
IAVI  [to 28 Mar 2020]
Press Releases
No new digest content identified.
International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
Global regulatory workshop on COVID-19 vaccine development (March 2020)
Global regulators have published a report today presenting the outcomes of a workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA).
The meeting report provides an overview of regulatory considerations related to COVID-19 vaccine development and data required for regulatory decision-making on two key points:
:: Pre-clinical data required to support proceeding to first-in-human clinical trials with investigational medicinal products; and
:: The need to address the known theoretical risk that vaccines against COVID-19 enhance the disease prior to starting first-in-human clinical trials.
All participants in the meeting acknowledged the urgency of conducting first-in-human clinical trials with COVID-19 vaccine candidates. The conclusions set out how regulatory authorities around the globe intend to strike the balance between rapid development of vaccines and the need to generate enough robust data to enable decision-making.
The meeting also aimed to encourage exchange of information about the global efforts towards developing new vaccines against COVID-19 through an open dialogue between medicines regulatory authorities around the globe.
About the workshop
The regulatory workshop was held virtually in the context of the ongoing COVID-19 pandemic. It brought together delegates from 17 different countries, representing more than 20 medicines regulatory authorities globally, as well as experts from the World Health Organization and the European Commission, to share their views on the development of vaccines against COVID-19. The meeting was co-chaired by EMA and the US Food and Drug Administration (FDA).
International Generic and Biosimilar Medicines Association [IGBA]
COVID-19 / Urgent call to governments – Air freight must reopen for critical medicines and supplies for their manufacture (March 2020)
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requested urgent action by governments and pharmaceutical supply chain stakeholders to reopen air freight routes and ensure patients around the globe can continue to have access to the medicines they need during the COVID-19 pandemic.

COVID-19: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity (March 2020)
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today calls upon the global policy leaders and governments to do everything in their power to keep the manufacturing operations and the supply chain of essential medicines operating at full capacity. This will allow our companies to continue to produce much needed critical medicines. While we support the need to protect healthcare workers and to provide hospitals with essential materials, putting unreasonable restrictions on exports of essential medical supplies or medicines will do more harm than good at this time of urgent need.
Press Releases
Jessica Pulay joins IFFIm Board of Directors
19 Mar 2020
Finance executive brings deep experience of public and private sector funding London, 19 March 2020 – Jessica Pulay has been appointed to the Board of Directors of IFFIm, the International Finance Facility for Immunisation, and will serve a three-year term effective 1 April 2020.

IFRC   [to 28 Mar 2020]
Selected Press Releases, Announcements
International Red Cross and Red Crescent Movement appeals for 800 million Swiss francs to assist world’s most vulnerable people in fight against COVID-19
Geneva, 26 March 2020 –-The International Red Cross and Red Crescent Movement on Thursday launched a revised emergency appeal for 800 million Swiss francs (823 million US dollars) to help the world’s most vulnerable communities halt the spread of COVID …
IVAC  [to 28 Mar 2020]
No new digest content identified.
IVI   [to 28 Mar 2020]
Selected IVI News & Announcements
No new digest content identified.
JEE Alliance  [to 28 Mar 2020]
Selected News and Events
No new digest content identified.
MSF/Médecins Sans Frontières  [to 28 Mar 2020]
Latest [Selected Announcements]
Coronavirus disease COVID-19
MSF calls for no patents or profiteering on COVID-19 drugs and vaccines
Press Release 27 Mar 2020
Geneva/New York — Médecins Sans Frontières (MSF) has called for no patents or profiteering on drugs, tests, or vaccines used for the COVID-19 pandemic, and for governments to prepare to suspend and override patents and take other measures, such as price controls, to ensure availability, reduce prices and save more lives.
Already, Canada, Chile, Ecuador and Germany have taken steps to make it easier to override patents by issuing ‘compulsory licences’ for COVID-19 medicines, vaccines and other medical tools. Similarly, the government of Israel issued a compulsory licence for patents on a medicine they were investigating for use for COVID-19…

MSF provides relief items and adapts response for COVID-1…
Project Update 27 Mar 2020

Coronavirus disease COVID-19
Preparation is key to cope with the COVID-19 pandemic in Côte d’Iv…
Project Update 27 Mar 2020

Coronavirus disease COVID-19
US must include asylum seekers in COVID-19 response, ra…
Press Release 27 Mar 2020

Coronavirus disease COVID-19
MSF steps up COVID-19 response with activities in Spain
Project Update 25 Mar 2020

Coronavirus disease COVID-19
MSF “deeply surprised” that Iranian authorities put a stop to our COVID-19 Response
Statement 25 Mar 2020

DRC Ebola outbreaks
How the Ebola response failed the people of DRC
Opinion 24 Mar 2020

Between war and fragile health systems, tackling TB in Sudan and Sou…
Voices from the Field 24 Mar 2020

Coronavirus disease COVID-19
COVID-19: Avoiding a ‘second tragedy’ for those with TB
Project Update 23 Mar 2020

Coronavirus disease COVID-19
MSF sends hospital and medical team to treat COVID-19 patients in …
Project Update 22 Mar 2020
National Vaccine Program Office – U.S. HHS  [to 28 Mar 2020]
NVAC 2020 Meetings
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)
NIH  [to 28 Mar 2020]
Selected News Releases
The National Library of Medicine expands access to coronavirus literature through PubMed Central
March 25, 2020 — PubMed Central is a digital archive of peer-reviewed biomedical and life sciences literature, with access to nearly 6 million full-text journal articles.

COVID-19 workers get training to protect their own health
March 23, 2020 — Special NIH program has trained workers through multiple national health emergencies.
PATH  [to 28 Mar 2020]
Selected Announcements
No new digest content identified.
Sabin Vaccine Institute  [to 28 Mar 2020]
Statements and Press Releases
Responding to COVID-19 – A Statement by the Sabin Vaccine Institute
Friday, March 27, 2020
UNAIDS [to 28 Mar 2020]
Selected Press Releases/Reports/Statements
27 March 2020
Strengthening services for violence against women and HIV in Indonesia
26 March 2020
Community members are driving the AIDS response in northern Myanmar

25 March 2020
Innovative and people-empowered approaches to end TB deaths
Thai hospitals to provide three- to six-month supplies of antiretroviral therapy

24 March 2020
Talking about a revolution
The volunteer driver in Wuhan

23 March 2020
Tuberculosis—good progress, but not enough

23 March 2020
Mining, drugs and conflict are stretching the AIDS response in northern Myanmar
UNICEF  [to 28 Mar 2020]
Press release
Despite challenges, UNICEF continues to ship vital supplies to affected countries amid soaring number of COVID-19 cases

Press release
UNICEF scales up support in 145 countries to keep children learning, as COVID-19 forces majority of schools worldwide to close

Statement by UNICEF Executive Director Henrietta Fore on the disruption of immunization and basic health services due to the COVID-19 pandemic

Press release
Global Partnership for Education announces US $8.8 million in funding to help UNICEF with COVID-19 response

Press release
A global approach is the only way to fight COVID-19, the UN says as it launches humanitarian response plan
COVID-19 Global Humanitarian Response Plan

UN launches global humanitarian response plan to COVID-19 pandemic
Remarks by UNICEF Executive Director Henrietta Fore (check against delivery)

Interruption to key water station in the northeast of Syria puts 460,000 people at risk as efforts ramp up to prevent the spread of Coronavirus disease
Statement from UNICEF Representative in Syria, Fran Equiza

Press release
COVID-19: More than 95 per cent of children are out of school in Latin America and the Caribbean

Vaccination Acceptance Research Network (VARN)  [to 28 Mar 2020]
No new digest content identified.
Vaccine Confidence Project  [to 28 Mar 2020]
Latest News & Archive
No new digest content identified.
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 28 Mar 2020]
Coronavirus Updates
Frequently Asked Questions about Coronavirus Disease 2019 (COVID-19)
Last Updated: March 19, 2020
Get some fast facts about the coronavirus from CHOP and the CDC. The CDC will provide updated information as it becomes available.
Wellcome Trust  [to 28 Mar 2020]
Opinion | 27 March 2020
A new way of developing vaccines for COVID-19 could help the world to prepare for future outbreaks [RNA vaccine development ]
Charlie Weller. Head of Vaccines Programme, Wellcome
The Wistar Institute   [to 28 Mar 2020]
Press Releases
No new digest content identified.
WFPHA: World Federation of Public Health Associations  [to 28 Mar 2020]
Latest News
No new digest content identified.
World Organisation for Animal Health (OIE)   [to 28 Mar 2020]
Press Releases
No new digest content identified.
ARM [Alliance for Regenerative Medicine]  [to 28 Mar 2020]
Press Releases
No new digest content identified.
BIO    [to 28 Mar 2020]
Press Releases
BIO Summit Accelerates Collaboration Between Government & Industry Leaders in Fight Against Covid-19
March 25, 2020
The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating Covid-19. The two-day virtual event helped companies working on treatments, diagnostics and vaccines come together to discuss challenges and opportunities with government officials and other stakeholders.

…Company leaders repeatedly expressed the need for speed of action on the part of government agencies to help accelerate the development of new diagnostics, treatments and vaccines. Also, as the discussions over two days unfolded, a number of key areas of concern emerged:

:: The need for innovative and flexible partnerships between industry, government and academia to quickly move the science through the development and regulatory processes;
:: The importance of determining how to best scale up manufacturing capacity when a new diagnostic, therapy or vaccine is available;
:: The urgency in securing funding for agencies and other partners to get resources where they are needed as soon as they are available; and
:: A desire to work with the FDA to establish guidelines for the development of point-of-care diagnostics.

… “Through the collaboration this virtual summit has helped foster,” said Greenwood, “I’m confident we will eradicate this deadly pandemic and be better prepared for the next one.”

To watch the opening plenary session of the virtual summit, click here.

To learn more about how the industry is responding to Covid-19, click here.

To see Jim Greenwood’s comments following the summit, click here.
DCVMN – Developing Country Vaccine Manufacturers Network  [to 28 Mar 2020]
No new digest content identified.
IFPMA   [to 28 Mar 2020]
Selected Press Releases, Statements, Publications
IFPMA Backgrounder – COVID-19
27 March 2020
[See COVID-19 for detail]
PhRMA    [to 28 Mar 2020]
Selected Press Releases, Statements
America’s Biopharmaceutical Companies are Supporting Italy During the Coronavirus Crisis
March 25, 2020
America’s biopharmaceutical companies stand with everyone affected by the coronavirus throughout Italy, and especially the patients and their loved ones, as well as the health care professionals and scientists fighting on the front lines…
Within Italy, biopharmaceutical companies are donating medicine, supplies and other expertise.
Specific company examples include:
:: Bristol-Myers Squibb contributed $1 million to the Red Cross in the Lombardy Region of Italy and donated face masks to local health care facilities.
:: Gilead has initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus.
:: The Lilly Italia Foundation is donating €1 million of insulin produced by Eli Lilly and Company.
:: Pfizer’s affiliate is donating €2.5 million worth of medicines and vaccines that can be used in the prevention and management of COVID-19 in impacted regions. Pfizer is also dedicating resources to ensure safe and timely home delivery of essential medicines for patients with life threatening and rare diseases, such as hemophilia.
:: Bayer is supporting hospitals in Lombardy, Italy, with a donation of €1 million that is helping procure urgently-needed equipment for intensive care units in hospitals with the greatest needs.
:: Novartis donated €1 million to the National Civil Protection in Campania, Italy.
:: Novo Nordisk offered direct financial support to hospitals most affected by the crisis. The company also set up an internal fundraising whereby the amount collected via the donations of employees will be doubled by the company and donated to the Italian Civil Protection Department. Additionally, Novo Nordisk sponsored an awareness campaign to provide basic information to the Italian elderly population on how they should respond during the coronavirus crisis and how to protect themselves against misinformation and fraud.
:: Sanofi is donating to support the National Civil Protection for the management of this emergency. The company also invited all employees in Italy to donate one hour or more of their work on a voluntary basis. Sanofi also donated €600,000. Additionally, Sanofi is ready to donate 200 thousand hydroxychloroquine-based treatments to the National Healthcare System, for Italian hospitals that will request them to treat patients with complications from COVID-19. In total, the company’s donations equal more than €2 million…


Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org